Coagulation Disorders DRG Reimbursement & Medicare

Acute hemostatic intervention trials: randomized or single-arm studies evaluating the efficacy and safety of immediate hemostatic strategies (for example, factor replacement dosing regimens, reversal agents for anticoagulation, or blood product protocols) in hospitalized patients presenting with active bleeding or severe coagulopathy. These studies focus on inpatients often in the emergency department, ICU, or perioperative setting who have acute bleeding related to congenital or acquired coagulation disorders, anticoagulant therapy, liver disease, or disseminated intravascular coagulation. Results are directly relevant to clinicians deciding rapid management pathways and to payers because they affect transfusion utilization, ICU length of stay, and short-term costs associated with bleeding complications.
Comparative effectiveness and dosing optimization studies: head-to-head or pragmatic trials comparing different maintenance strategies for preventing bleeding events in patients with chronic coagulation disorders (such as prophylactic versus on-demand factor replacement, alternative dosing schedules, or different formulations). These trials enroll outpatients with recurrent bleeding risk or recently discharged patients transitioning to maintenance therapy, and measure outcomes including breakthrough bleeding rates, hospital readmissions, infusion-related adverse events, and resource use. Payers and providers benefit from evidence on which long-term regimens reduce hospitalization and downstream costs while maintaining safety and quality of life for patients in this DRG.
Post-discharge outcomes and care-pathway implementation studies: observational cohorts or quality-improvement trials assessing multidisciplinary discharge strategies, patient education, adherence monitoring, and outpatient follow-up models to reduce readmissions and complications among patients hospitalized for coagulation disorders. Populations include survivors of severe bleeding episodes, patients newly started on anticoagulation reversal protocols, and those with complex comorbidities like liver disease who require coordinated care. This research identifies system-level interventions that influence 30‑ and 90‑day readmission rates, outpatient utilization, and total cost of care—key metrics for hospitals and insurers managing DRG-based reimbursement.

Acute hemostatic intervention trials: randomized or single-arm studies evaluating the efficacy and safety of immediate hemostatic strategies (for example, factor replacement dosing regimens, reversal agents for anticoagulation, or blood product protocols) in hospitalized patients presenting with active bleeding or severe coagulopathy. These studies focus on inpatients often in the emergency department, ICU, or perioperative setting who have acute bleeding related to congenital or acquired coagulation disorders, anticoagulant therapy, liver disease, or disseminated intravascular coagulation. Results are directly relevant to clinicians deciding rapid management pathways and to payers because they affect transfusion utilization, ICU length of stay, and short-term costs associated with bleeding complications.
Comparative effectiveness and dosing optimization studies: head-to-head or pragmatic trials comparing different maintenance strategies for preventing bleeding events in patients with chronic coagulation disorders (such as prophylactic versus on-demand factor replacement, alternative dosing schedules, or different formulations). These trials enroll outpatients with recurrent bleeding risk or recently discharged patients transitioning to maintenance therapy, and measure outcomes including breakthrough bleeding rates, hospital readmissions, infusion-related adverse events, and resource use. Payers and providers benefit from evidence on which long-term regimens reduce hospitalization and downstream costs while maintaining safety and quality of life for patients in this DRG.
Post-discharge outcomes and care-pathway implementation studies: observational cohorts or quality-improvement trials assessing multidisciplinary discharge strategies, patient education, adherence monitoring, and outpatient follow-up models to reduce readmissions and complications among patients hospitalized for coagulation disorders. Populations include survivors of severe bleeding episodes, patients newly started on anticoagulation reversal protocols, and those with complex comorbidities like liver disease who require coordinated care. This research identifies system-level interventions that influence 30‑ and 90‑day readmission rates, outpatient utilization, and total cost of care—key metrics for hospitals and insurers managing DRG-based reimbursement.

OpenPayer

Summary & Overview

Coagulation Disorders: Inpatient Reimbursement Overview

DRG 813 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes